
Corneal cross-linking can halt the progression of keratoconus, but what is the best approach for treatment? There are a number of treatment options for keratoconus, but only corneal cross-linking (CXL) appears to halt the progression of the disease. To guarantee effective cross-linking, CXL treatment involves removal of the corneal epithelium prior to riboflavin application and ultraviolet light illumination - "epi-off" CXL. Several methods of "epi-on" (transepithelial) CXL have been proposed, such as keeping the corneal epithelium intact which should be less painful and help avoid other CXL-associated adverse events. The evidence so far is that epi-off CXL remains the most effective method of strengthening the cornea and slowing keratoconus progression - but transepithelial methods are gaining ground.
Evidence-Based Medicine, Photosensitizing Agents, Riboflavin, Epithelium, Corneal, Keratoconus, Combined Modality Therapy, Cross-Linking Reagents, Treatment Outcome, Photochemotherapy, Humans, Ultraviolet Therapy
Evidence-Based Medicine, Photosensitizing Agents, Riboflavin, Epithelium, Corneal, Keratoconus, Combined Modality Therapy, Cross-Linking Reagents, Treatment Outcome, Photochemotherapy, Humans, Ultraviolet Therapy
| selected citations These citations are derived from selected sources. This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically). | 1 | |
| popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network. | Average | |
| influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically). | Average | |
| impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network. | Average |
